Pharmaceutical

Alvotech and Advanz to commercialise biosimilars in Europe

Alvotech and UK-based Advanz Pharma sign agreement to commercialise three additional biosimilar candidates in Europe.

Jun 1, 2025 - 06:00
Alvotech and Advanz to commercialise biosimilars in Europe
Alvotech and UK-based Advanz Pharma sign agreement to commercialise three additional biosimilar candidates in Europe.
Read the original article

Tags:

Previous Article

EyePoint advances with Duravyu Phase III trial

Next Article

FDA rejects Stealth Bio’s Barth syndrome treatment after 16.5-month review

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Cristália signs licensing deal for Formosa’s APP13007

Cristália signs licensing deal for Formosa’s APP13007

Jan 29, 2024

FDA grants priority review for Takeda and HUTCHMED’s fruquintinib NDA

FDA grants priority review for Takeda and HUTCHMED’s fr...

May 26, 2023

The unmet need in T2-low asthma: A critical gap in treatment

The unmet need in T2-low asthma: A critical gap in trea...

Jan 4, 2025